Panlong Pharmaceutical released its 2026 interim report on August 27. First-half operating revenue was 423 million yuan, down 26.4 percent year on year, and net profit attributable to the parent company was 42.38 million yuan, down 29.5 percent year on year. The company also announced the termination of the Qinling Rehabilitation Hospital project invested and constructed by its subsidiary Shaanxi Panlonggu Culture, Tourism and Health Care Company. The project had an estimated investment of 180 million yuan, with about 3.53 million yuan already invested, and is no longer feasible due to changes in policy and market conditions. In addition, Chief Financial Officer Zhu Fengming resigned for personal health reasons.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class AFirst-half revenue and net profit declined significantly, and the company terminated a 180 million yuan rehabilitation hospital project due to policy and market changes.
